Fig. 4
From: Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy
EVs-Cas9-29b attenuates muscle atrophy in vitro. a Immunofluorescent staining and quantification (n = 4 per group; scale bar: 100 μm; Green, MF-20, represents the myotube); qRT-PCR analysis of Atrogin-1 and MuRF-1 expression (n = 6 per group) in C2C12 myotubes after treatment with EVs-Cas9-29b in Dex-induced muscle-atrophy model. b Immunofluorescent staining and quantification (n = 4 per group; scale bar: 100 μm; Green, MF-20, represents the myotube); qRT-PCR analysis of Atrogin-1 and MuRF-1 expression (n = 6 per group) in C2C12 myotubes after treatment with EVs-Cas9-29b in Ang II-induced muscle-atrophy model. c Immunofluorescent staining and quantification (n = 4 per group; scale bar: 100 μm; Green, MF-20, represents the myotube); qRT-PCR analysis of Atrogin-1 and MuRF-1 expression (n = 6 per group) in C2C12 myotubes after treatment with EVs-Cas9-29b in TNF-α-induced muscle-atrophy model. Data were presented as Mean ± SD. Statistical significance was determined by Two-way ANOVA with Tukey test (a-c). *P < 0.05; **P < 0.01 and ***P < 0.001